Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | PNMT | P11086 | 6/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.31 |
| ▸ | PRF1 | P14222 | 1/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11017385 | 0.73 | TRPA1 (0.44) | TRPA1PNMTDRD2DRD3NOS3 | |
| SCHEMBL28039609 | 0.70 | PNMT (0.42) | TRPA1PNMTDRD2DRD3NOS3 | |
| Water SCHEMBL28095232 | 0.69 | PNMT (0.49) | TRPA1PNMTDRD2DRD3NOS3 | |
| SCHEMBL21391039 | 0.67 | TRPA1 (0.39) | TRPA1PNMTDRD2DRD3NOS3 | |
| SCHEMBL6739755 | 0.66 | — | — | |
| SCHEMBL2809825 | 0.66 | PNMT (0.48) | TRPA1PNMTDRD2DRD3KDM1A | |
| SCHEMBL31545183 | 0.66 | PNMT (0.48) | TRPA1PNMTDRD2DRD3KDM1A | |
| SCHEMBL11908201 | 0.66 | PNMT (0.41) | TRPA1PNMTDRD2DRD3NOS3 | |
| SCHEMBL7647780 | 0.66 | PNMT (0.44) | TRPA1PNMTDRD2DRD3NOS3 | |
| Bromide SCHEMBL17202846 | 0.65 | PNMT (0.52) | TRPA1PNMTDRD2DRD3KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115385903-A | Preparation method of cyano-substituted benzoxazine-4-one derivative | 江苏扬农化工股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-8163740-B2 | 6-substituted benzoxazines | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063037-A1 | 6-SUBSTITUTED BENZOXAZINES | HTR5A, NPY5R, GABRA5 | TRPA1 850/4885PNMT 429/4885DRD2 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.